Michael Jon Brown Sells 13,000 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 13,000 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

DexCom Price Performance

DexCom stock traded down $0.65 during midday trading on Tuesday, reaching $70.70. The company had a trading volume of 2,603,968 shares, compared to its average volume of 3,881,061. The company has a market capitalization of $27.63 billion, a P/E ratio of 49.44, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm's fifty day simple moving average is $83.82 and its 200-day simple moving average is $76.94. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Remove Ads

Institutional Trading of DexCom

A number of hedge funds have recently bought and sold shares of the business. Forvis Mazars Wealth Advisors LLC lifted its position in shares of DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after purchasing an additional 118 shares during the last quarter. Principal Securities Inc. lifted its position in shares of DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after purchasing an additional 135 shares during the last quarter. Larson Financial Group LLC lifted its position in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Nia Impact Advisors LLC raised its stake in DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after acquiring an additional 140 shares in the last quarter. Finally, Level Four Advisory Services LLC raised its stake in DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock worth $1,026,000 after acquiring an additional 150 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Citigroup upped their price target on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Canaccord Genuity Group upped their price target on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and increased their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.